1. XY Chi#, RH Yan#, J Zhang#, GY Zhang, YY Zhang, M Hao, Z Zhang, PF Fan, YZ Dong, YL Yang, ZS Chen, YY Guo, JL Zhang, YN Li, XH Song, Y Chen, L Xia, L Fu, LH Hou, JJ Xu, CM Yu, JM Li*, Q Zhou*, W Chen*. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020, 369(6504): 650-655.

2. FC Zhu#*, XH Guan#, YH Li, JY Huang, T Jiang, LH Hou, JX Li, BF Yang, L Wang, WJ Wang, SP Wu, Z Wang, XH Wu, JJ Xu, Z Zhang, SY Jia, BS Wang, Y Hu, JJ Liu, J Zhang, X’A Qian, Q Li, HX Pan, HDC Jiang, P Deng, JB Gou, XW Wang, XH Wang*, W Chen*. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 2020, 396(10249): 479-488.

3. FC Zhu#*, YH Li#, XH Guan, LH Hou, WJ Wang, JX Li, SP Wu, BS Wang, Z Wang, L Wang, SY Jia, HDC Jiang, L Wang, T Jiang, Y Hu, JB Gou, SB Xu, JJ Xu, XW Wang, W Wang*, W Chen*. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet, 2020, 395(10240): 1845-1854.

4. FC Zhu#, AH Wurie#, LH Hou, Q Liang, YH Li, JBW Russell, SP Wu, JX Li, YM Hu, Q Guo, WB Xu, AR Wurie, WJ Wang, Z Zhang, WJ Yin, M Ghazzawi, X Zhang, L Duan, JZ Wang*, W Chen*. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 2017, 389(10069): 621-628.

5. FC Zhu, LH Hou, JX Li, SP Wu, P Liu, GR Zhang, YM Hu, FY Meng, JJ Xu, R Tang, JL Zhang, WJ Wang, L Duan, K Chu, Q Liang, JL Hu, L Luo, T Zhu, JZ Wang, W Chen*. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet, 2015, 385(9984): 2272-2279.

1. 国家杰出青年科学基金（81025018），特种药物，2011/01-2014/12，主持

2. 国家重点研发计划（2020YFC0849800），重组新型冠状病毒疫苗（腺病毒载体）研发，2020/01-2020/09，主持

1. XY Chi#, RH Yan#, J Zhang#, GY Zhang, YY Zhang, M Hao, Z Zhang, PF Fan, YZ Dong, YL Yang, ZS Chen, YY Guo, JL Zhang, YN Li, XH Song, Y Chen, L Xia, L Fu, LH Hou, JJ Xu, CM Yu, JM Li*, Q Zhou*, W Chen*. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020, 369(6504): 650-655.

2. FC Zhu#*, XH Guan#, YH Li, JY Huang, T Jiang, LH Hou, JX Li, BF Yang, L Wang, WJ Wang, SP Wu, Z Wang, XH Wu, JJ Xu, Z Zhang, SY Jia, BS Wang, Y Hu, JJ Liu, J Zhang, X’A Qian, Q Li, HX Pan, HDC Jiang, P Deng, JB Gou, XW Wang, XH Wang*, W Chen*. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 2020, 396(10249): 479-488.

3. FC Zhu#*, YH Li#, XH Guan, LH Hou, WJ Wang, JX Li, SP Wu, BS Wang, Z Wang, L Wang, SY Jia, HDC Jiang, L Wang, T Jiang, Y Hu, JB Gou, SB Xu, JJ Xu, XW Wang, W Wang*, W Chen*. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet, 2020, 395(10240): 1845-1854.

4. FC Zhu#, AH Wurie#, LH Hou, Q Liang, YH Li, JBW Russell, SP Wu, JX Li, YM Hu, Q Guo, WB Xu, AR Wurie, WJ Wang, Z Zhang, WJ Yin, M Ghazzawi, X Zhang, L Duan, JZ Wang*, W Chen*. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 2017, 389(10069): 621-628.

5. FC Zhu, LH Hou, JX Li, SP Wu, P Liu, GR Zhang, YM Hu, FY Meng, JJ Xu, R Tang, JL Zhang, WJ Wang, L Duan, K Chu, Q Liang, JL Hu, L Luo, T Zhu, JZ Wang, W Chen*. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet, 2015, 385(9984): 2272-2279.

国家技术发明二等奖（2016-1）、军队科技进步一等奖（2006-1）、中国十大杰出青年（2003）、中国青年女科学家奖（2011）、何梁何利科学与技术进步奖（2017）、全国优秀共产党员（2020）、“人民英雄”国家荣誉称号（2020）、集体一等功（2020）。

1. 陈薇、徐俊杰、郭强等，分泌型大肠杆菌表达载体及其应用，ZL200410074359.X，2007-10-31

2. 陈薇、吴诗坡、侯利华等，Ebola virus disease vaccine taking human replication deficient adenovirus as vector，US10172932，2019-1-8

3. 陈薇、吴诗坡、侯利华等，一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗，ZL202010193587.8，2020-9-11

4. 陈薇、宰晓东、徐俊杰等，基于机器学习技术预测细菌保护性抗原蛋白的方法及系统，ZL201910264168.6，2021-10-22

5. 陈薇、于长明、李建民等，一种全人源抗新冠病毒中和抗体ZW2G10及应用，ZL202210023619.9，2022-3-25